secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001213900-25-043362
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025
-------------------------------------------------------------------------------

- Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.
- Cash and cash equivalents only $26,410 as of March 31, 2025.
- Company will need additional capital to support operations beyond May 2025.
- R&D expenses $3.8M; G&A expenses $4.8M, both up vs prior year.
- Plans to secure financing for LYMPHIR launch; retained Jefferies for strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/0001213900-25-043362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025043362/ea0241974-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer